Ojjaara is an oral medication for adults with intermediate or high-risk myelofibrosis and anemia. It targets JAK1, JAK2, and ACVR1 to reduce spleen size, relieve symptoms, and improve anemia.
Approval Date
15-Sep-23
NCE-1 Date
15-Sep-27
NCE Date
15-Sep-28
Commercial snapshot
Market performance & projections
Revenue ($M)
730
CAGR (%)
16.38%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
976
2027
1,166
2028
1,264
2029
1,339
2030
1,407
2031
1,476
2032
1,543
Molecule profile
Details & specifications
Molecule
Momelotinib
Innovator
GLAXOSMITHKLINE LLC
Dosage Form
Tablet
Strength
100 mg, 150 mg and 200 mg
Therapeutic Category
Anticancer
Usage
To treat intermediate or high-risk myelofibrosis in adults with anemia
Good to know
Frequently asked questions
Ready to act on this opportunity?
Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.